CDK2AP2P2: A Potential Drug Target and Biomarker for Cancer (G107133486)

Target Name: CDK2AP2P2

NCBI ID: G107133486

CDK2AP2P2

Other Name(s): cyclin dependent kinase 2 associated protein 2 pseudogene 2 | Cyclin dependent kinase 2 associated protein 2 pseudogene 2

CDK2AP2P2: A Potential Drug Target and Biomarker for Cancer

Cyclin dependent kinase 2 (CDK2) is a key regulator of cell cycle progression and has been implicated in various diseases, including cancer. The CDK2 signaling pathway has been implicated in the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. CDK2 has also been implicated in the regulation of cell survival and has been implicated in the development of neurodegenerative diseases.

CDK2AP2P2, also known as cyclin dependent kinase 2 associated protein 2 pseudogene 2, is a protein that is expressed in various tissues and cells, including cancer cells. It is a key regulator of the CDK2 signaling pathway and has been implicated in the development and progression of many types of cancer.

CDK2AP2P2 functions as a negative regulator of the CDK2 signaling pathway. It inhibits the activity of the CDK2 protein, which in turn regulates the progression of cells through the cell cycle. The CDK2AP2P2 protein has been shown to play a role in the regulation of cell cycle progression and has been implicated in the development and progression of many types of cancer.

CDK2AP2P2 has also been shown to function as a potential drug target in cancer. By inhibiting the activity of CDK2AP2P2, researchers have been able to inhibit the progression of cancer cells through the cell cycle, leading to the potential for the development of cancer therapies.

CDK2AP2P2 has also been shown to function as a biomarker for cancer. The expression of CDK2AP2P2 has been shown to be associated with the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. This suggests that CDK2AP2P2 may be a useful biomarker for the diagnosis and treatment of cancer.

CDK2AP2P2 as a drug target

CDK2AP2P2 has been shown to be a potential drug target for cancer. By inhibiting the activity of CDK2AP2P2, researchers have been able to inhibit the progression of cancer cells through the cell cycle, leading to the potential for the development of cancer therapies.

One of the main strategies for targeting CDK2AP2P2 is the use of small molecules, such as inhibitors, that can inhibit the activity of the CDK2AP2P2 protein. These inhibitors have been shown to be effective in inhibiting the progression of cancer cells through the cell cycle.

Another approach for targeting CDK2AP2P2 is the use of monoclonal antibodies, which are laboratory mice that are designed to specifically bind to the CDK2AP2P2 protein. These antibodies have been shown to be effective in inhibiting the progression of cancer cells through the cell cycle.

CDK2AP2P2 as a biomarker

CDK2AP2P2 has also been shown to function as a biomarker for cancer. The expression of CDK2AP2P2 has been shown to be associated with the development and progression of many types of cancer, including breast, ovarian, and prostate cancer. This suggests that CDK2AP2P2 may be a useful biomarker for the diagnosis and treatment of cancer.

One of the main applications of CDK2AP2P2 as a biomarker is its potential use in the development of personalized medicine. By using information about an individual's CDK2AP2P2 expression, doctors can determine the most effective treatment for that individual, leading to a more effective and personalized treatment plan.

Conclusion

CDK2AP2P2 is a protein that is expressed in various tissues and cells, including cancer cells. It is a key regulator of the CDK2 signaling pathway and has

Protein Name: Cyclin Dependent Kinase 2 Associated Protein 2 Pseudogene 2

The "CDK2AP2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK2AP2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets